Chinese regulators are implementing stricter scrutiny over offshore incorporation vehicles, making it harder for tech and biotech companies to conduct IPOs. This move is indicative of Beijing's increased caution in overseeing sensitive industries and ensuring comprehensive regulatory oversight.

US dollar-denominated funds could face more hurdles when investing in Chinese tech and biotech companies as Beijing adopts a stricter approach to companies seeking listings via offshore incorporated vehicles. Indicative of Chinese regulators’ caution in overseeing sensitive industries, industry sources say the move ensures that any sale of assets does not escape regulatory scrutiny. And for any offshore incorporated structures that are approved, the stock regulator requires listing applicants to...